Wall Street analysts predict that Sierra Oncology Inc (NASDAQ:SRRA) will post earnings per share of ($0.21) for the current quarter, Zacks reports. Zero analysts have provided estimates for Sierra Oncology’s earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.17). Sierra Oncology reported earnings per share of ($0.20) during the same quarter last year, which suggests a negative year-over-year growth rate of 5%. The firm is expected to report its next earnings report on Tuesday, February 26th.
According to Zacks, analysts expect that Sierra Oncology will report full year earnings of ($0.77) per share for the current fiscal year, with EPS estimates ranging from ($0.80) to ($0.73). For the next financial year, analysts forecast that the business will report earnings of ($0.80) per share, with EPS estimates ranging from ($0.95) to ($0.66). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Sierra Oncology.
Sierra Oncology (NASDAQ:SRRA) last announced its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03).
Large investors have recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Sierra Oncology by 25.5% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,950 shares of the biotechnology company’s stock valued at $305,000 after acquiring an additional 20,950 shares during the period. UBS Group AG bought a new position in Sierra Oncology in the first quarter valued at about $111,000. Bridgeway Capital Management Inc. lifted its holdings in Sierra Oncology by 36.9% in the third quarter. Bridgeway Capital Management Inc. now owns 225,000 shares of the biotechnology company’s stock valued at $383,000 after acquiring an additional 60,700 shares during the period. 683 Capital Management LLC lifted its holdings in Sierra Oncology by 3.5% in the second quarter. 683 Capital Management LLC now owns 1,800,000 shares of the biotechnology company’s stock valued at $5,328,000 after acquiring an additional 60,926 shares during the period. Finally, Acadian Asset Management LLC lifted its holdings in Sierra Oncology by 22.4% in the third quarter. Acadian Asset Management LLC now owns 386,351 shares of the biotechnology company’s stock valued at $656,000 after acquiring an additional 70,724 shares during the period. 60.50% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:SRRA traded down $0.02 during midday trading on Monday, reaching $1.52. 168,578 shares of the company’s stock traded hands, compared to its average volume of 480,833. The company has a market cap of $114.52 million, a P/E ratio of -1.81 and a beta of 1.72. The company has a debt-to-equity ratio of 0.05, a current ratio of 14.68 and a quick ratio of 14.68. Sierra Oncology has a one year low of $1.48 and a one year high of $4.09.
Sierra Oncology Company Profile
Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.
Recommended Story: NASDAQ
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.